[Form 4] BioLife Solutions Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 219 shares of common stock on 08/26/2025 at $25.44 per share under a pre-established Rule 10b5-1(c) plan. The filing states the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported transaction, the reporting person beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.

The sale was made pursuant to a 10b5-1 trading plan adopted 02/24/2022, which the filer checked on the form to indicate pre-planned execution; the Form 4 is signed and dated 08/28/2025.

Positive

• Sale executed under a Rule 10b5-1(c) trading plan, indicating the transaction was pre-planned and not opportunistic
• Purpose of sale disclosed (to satisfy tax withholding on restricted stock vesting), improving transparency
• Insider retains a substantial direct stake (78,304 shares) after the transaction

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine, small insider sale under a 10b5-1 plan to cover tax withholding; immaterial to outstanding share count.

The transaction is a disposal of 219 shares at $25.44 under a documented Rule 10b5-1(c) plan, adopted 02/24/2022, and intended to satisfy tax withholding from restricted stock vesting. With 78,304 shares remaining beneficially owned directly after the sale, this represents a very small percentage change in the insider's stake and is unlikely to affect market valuation or signal a change in company fundamentals. The filing is standard, properly signed, and discloses the plan-based execution.

Corporate Governance Expert

TL;DR: Disclosure follows governance best practices: pre-arranged plan flagged and purpose stated, improving transparency.

The reporting clearly marks the transaction as executed under a 10b5-1(c) plan and provides the specific adoption date of that plan. Stating the sale was to satisfy tax withholding obligations tied to restricted stock vesting is consistent with good insider disclosure practices. The limited size of the sale (219 shares) and continued direct ownership of 78,304 shares suggest no material change in alignment between management and shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025		S(1)		219	D	$25.44	78,304	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Sarah Aebersold	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioLife (BLFS) insider Sarah Aebersold sell on 08/26/2025?

She sold 219 shares of BioLife Solutions common stock on 08/26/2025 at a price of $25.44 per share.

Why was the sale by Sarah Aebersold made under a 10b5-1 plan?

The Form 4 states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations from restricted stock vesting.

How many BioLife shares does Sarah Aebersold own after the reported transaction?

Following the reported sale, she beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.

Does the Form 4 indicate the reporting person's role at BioLife?

Yes. The form identifies Sarah Aebersold as an Officer, specifically the Chief Human Resources Officer.

When was the Form 4 signed and filed?

The Form 4 is signed by Sarah Aebersold and dated 08/28/2025.